| Literature DB >> 35268439 |
Antonio Rosales-Castillo1,2, Gemma Jiménez-Guerra3, Lara Ruiz-Gómez4, Manuela Expósito-Ruíz5, José María Navarro-Marí3, José Gutiérrez-Fernández2,3,4.
Abstract
The detection of emerging pathogens responsible for genitourinary infections has increased with technological advances. We conducted a systematic review of publications on the involvement of these microorganisms in genitourinary samples, and we also investigated their presence and antibiotic susceptibility in samples from patients at our regional hospital (Granada, Spain). The MEDLINE database was searched up to 31 December 2020, and a cross-sectional descriptive study was performed of results obtained in urine samples and genital exudates from January 2016 through December 2019. The review highlighted the frequent involvement of Neisseria meningitidis in genital infections, while the data on other microorganisms were consistent with findings in our patient series. The emerging microorganisms most often responsible for urinary tract infections were Streptococcus bovis (58.5%) and Gardnerella vaginalis (23.6%) in females, and S. bovis (32.3%), Aerococcus urinae (18.6%), and Corynebacterium spp. (16.9%) in males; those most frequently reported in genital infections were S. viridans (36.4%) in females and C. glucuronolyticum (32.2%) and G. vaginalis (35.6%) in males. In general, emerging pathogens are resistant to conventional antibiotics such as penicillin. However, there has also been an increase in beta-lactam resistance by the S. bovis group and Corynebacterium spp. The systematic review showed that emerging microorganisms are responsible for only a small percentage of genitourinary infections but are of major clinical interest, with a predominance of the S. bovis group, G. vaginalis, Lactobacillus spp., Aerococcus spp., and Corynebacterium spp. in urine samples and of G. vaginalis and C. glucuronolyticum in genital samples. Given the increasing resistance to antibiotics empirically prescribed in patients with genitourinary infections, it is recommended to create an antibiogram in all cases.Entities:
Keywords: balano-posthitis bacteria; cervix bacteria; emerging pathogens; epididymitis bacteria; prostatitis bacteria; urethritis bacteria; urinary tract infection; vaginitis bacteria
Year: 2022 PMID: 35268439 PMCID: PMC8911399 DOI: 10.3390/jcm11051348
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Articles in the systematic review on emerging microorganisms in urinary tract infections.
| Article | Age-Sex | Predisposing Factors | Microorganism | Clinical Manifestations | Clinical Sample | Treatment | Microbiological Identification Method |
|---|---|---|---|---|---|---|---|
| Vedel G et al., 2006 | 64-Male | Recurrent urolithiasis |
| Urinary tract infection | Urine | Norfloxacin | RNAr 16S gene sequencing |
| El Sayegh H et al., 2007 | 61-Male | Vesicocutaneous fistula |
| Cystitis | Urine | Quinolones | Not described |
| Perciaccante A et al., 2007 | 57-Male | Systemic lupus erythematosus |
| Cystitis | Urine | Teicoplanin | Not described |
| Beteta A et al., 2009 | 34-Female | Not described |
| Urinary tract infection | Urine | Ciprofloxacin | API Coryne (BioMérieux) |
| Larios OE et al., 2010 | 76-Female | Recurrent urinary tract infection |
| Urinary tract infection | Urine | Clindamycin | Not described |
| Zimmermann P et al., 2012 | 8-Male | Neurogenic bladder dysfunction |
| Urinary tract infection | Urine | Trimethoprim-Sulfamethoxazo-le | RNAr 16S gene sequencing |
| Barberis C et al., 2018 | 36-Female | Chronic renal failure |
| Urinary tract infection | Urine | Piperacillin/tazo-bactam Ciprofloxacin | MALDI-TOF |
| Jiménez G et al., 2018 | 80-Male | Benign prostate hypertrophy |
| Urinary septic shock | Urine | Amoxicilin-clavulanic acid | MALDI-TOF |
| 88-Male | Not described |
| Urinary tract infection | Urine | Cefuroxime | MALDI-TOF | |
| Lorenzin G et al., 2018 | 69-Male | Type 2 diabetes mellitus |
| Urinary tract infection | Urine | Trimethoprim-Sulfamethoxazo-le | MALDI-TOF |
| Figueroa F et al., 2019 | 55-Male | Not described |
| Urinary tract infection Mitral valve endocarditis | Urine | Gentamicin | Not described |
| Pichon M et al., 2019 | 67-Female | Neurogenic bladder |
| Urinary sepsis | Urine | Amoxicilin | MALDI-TOF |
| Napolitani M et al., 2019 | 20-Male | Suprapubic catheter |
| Urinary tract infection | Not described | Not described | Not described |
Articles in the systematic review on emerging microorganisms in urethritis.
| Article | Age-Sex | Predisposing Factors | Microorganism | Clinical Manifestations | Clinical Sample | Treatment | Microbiological Identification Method |
|---|---|---|---|---|---|---|---|
| Gregory JE et al., 1979 | 27-Male | Alcohol abuse |
| Urethritis | Urethral exudate | Procaine penicillin | Not described |
| Karolus JJ et al., 1980 | 29-Male | Oral-genital and vaginal contact |
| Urethritis | Urethral exudate | Procaine penicillin | Not described |
| Chowdhury MNH et al., 1984 | 35-Male | Sexual relations with female partner (non- extramarital, oral-genital, or anal) | Urethritis | Urethral exudate | Phenoxymethylpenicillin | Not described | |
| Noble RC et al., 1985 | 25-Male | Vaginal and oral sexual relation with a female |
| Urethritis | Urethral exudate | Ampicillin | Not described |
| Hay PE et al., 1989 | 16-Male | Oral sex (female) |
| Urethritis | Urethral exudate | Spectinomycin | Not described |
| Wilson APR et al., 1989 | 18-Male | Sexual relations with steady partner (female) |
| Urethritis | Urethral exudate | Ampicillin | Not described |
| Phillips EA et al., 1989 | 19-Male | Sexual contact (female) |
| Urethritis | Urethral exudate | Amoxicillin | Not described |
| Shanmugaratnam K et al., 1989 | 25-Male | Oral-genital contact |
| Urethritis | Urethral exudate | Ciprofloxacin | Not described |
| Faigel HC et al., | 20-Male | Oral-genital contact (female) |
| Urethritis | Urethral exudate | Not described | Not described |
| Coker DM et al., 1991 | 36-Male | Sporadic sexual relations (female) |
| Urethritis | Urethral exudate | Ciprofloxacin | Not described |
| Quarto M et al., | 35-Male | Occasional oral sex with a female |
| Urethritis | Urethral exudate | Ampicillin | Not described |
| Kanemitsu N et al., 2003 | 48-Male | Oral-genital contact |
| Urethritis | Urethral exudate | Levofloxacin | Enzymatic profiles |
| Orden B et al., 2004 | 36-Male | Unprotected oral and vaginal sexual relations |
| Urethritis | Urethral exudate | Ceftriaxone | API NH (bioMérieux) |
| Rodríguez CN et al., 2005 | 27-Male | Oral and vaginal sexual relations with several women |
| Urethritis | Urethral exudate | Ceftriaxone | API NH (bioMérieux) |
| Urra E et al., 2005 | 38-Male | Sexual relations with steady partner (female) |
| Urethritis | Urethral exudate | Minocycline | API NH (bioMérieux) |
| Abdolrasouli A et al., 2007 | 23-Male | Unprotected fellatio |
| Urethritis | Urethral and throat exudate | Ciprofloxacin | Not described |
| Koroglu M et al., 2007 | 43-Male | Multiple sexual partners |
| Urethritis | Urethral exudate | Amoxicillin | BD BBL Crystal test |
| Galán-Sánchez F et al., 2011 | 18-Male | Sexual relations with multiple partners |
| Urethritis | Urethral exudate | Ciprofloxacin | API Coryne sistem |
| Katz AR et al., 2011 | 26-Male | Oral and vaginal sex with one woman |
| Urethritis | Urethral exudate | Cefixime | API NH (bioMérieux) |
| Bousquet A et al., 2012 | 35-Male | Unprotected oral-genital sex with males and females |
| Urethritis | Urethral exudate | Ceftriaxone | MALDI-TOF |
| Abdolrasouli A et al., 2013 | 27-Male | Possible unprotected sexual relations |
| Urethritis | Urethral exudate | Azithromycin | API Coryne system (bioMérieux) |
| Babics A et al., 2015 | 36-Male | Not described |
| Urethritis | Urine | Azithromycin | MALDI-TOF (Bruker) |
| Gherardi G et al., 2015 | 37-Male | Not described |
| Genitourinary tract infection | Urethral exudate | Ciprofloxacin | MALDI-TOF |
| Seynabou Lo et al., 2015 | 52-Male | Previous urethroplasties |
| Urinary tract infection | Urine | Imipenem | MALDI-TOF |
| Grandolfo M et al., 2016 | 39-Male | Not described |
| Purulent balanoposthitis | Urethral exudate | Ceftriaxone | Vitek 2 compact system (bioMérieux) |
| Jannic A et al., 2019 | 22-Male | Sexual relations with steady partner (female) |
| Urethritis | Urethral exudate | Ceftriaxone | MALDI-TOF |
Articles in the systematic review on emerging microorganisms in episodes other than urethritis.
| Article | Age-Sex | Predisposing Factors | Microorganism | Clinical Manifestations | Clinical Sample | Treatment | Microbiological Identification Method |
|---|---|---|---|---|---|---|---|
|
| |||||||
| Jaffe LR et al., 1983 | 16-Female | Not described |
| Pelvic inflammatory disease | Vaginal exudate | Procaine penicillin | Not described |
| Quentin R et al., 1991 | 80-Female | Genital adenocarcinoma |
| Metrorrhagia | Vaginal exudate | Amoxicillin- clavulanic acid | Not described |
| Harriau P et al., 1997 | 19-Female | Pregnancy |
| Endocervical infection | Endocervical exudate | Amoxicillin | Not described |
|
| |||||||
| Greif Z et al., 1986 | 34-Female | Contact with farm parasites and birds |
| Septicemia | Blood | Cephalotin Tobramycin | Not described |
| Vila de Muga M et al., 2008 | 5-Female | Not described |
| Vaginitis-peritonitis | Vaginal exudate | Ceftriaxone | Not described |
| Chen X et al., 2015 | 9-Female | Not described |
| Vaginitis | Vaginal exudate | Topical benzalkonium chloride | Vitek-2 compact bacterial identification system (bioMérieux) |
| Gómez C et al., 2018 | 28-Female | Not described |
| Tumor in right groin | Vaginal exudate | Azithromycin | MALDI-TOF |
|
| |||||||
| Grandolfo M et al., 2016 | 39-Male | Not described |
| Purulent balanoposthitis Urethritis | Urethral exudate | Ceftriaxone | Vitek 2 compact system (bioMérieux) |
|
| |||||||
| Nguyen C et al., 1990 | 39-Male | Suprapubic removal of vesical calculus |
| Prostatic abscess | Purulent abscess material | Ampicillin | Not described |
| QU L et al., 2003 | 37-Male | Transplantation of part of the intestine (Crohn’s disease) |
| Prostatitis | Urine | Ciprofloxacin | Not described |
| Martinaud C et al., 2008 | 92-Male | Prostatic adenoma |
| Sepsis | Urine | Ofloxacin | RNAr 16S gene sequencing |
| Torres E et al., 2013 | 48-Male | Arterial hypertension Left ventricular hypertrophy |
| Prostatitis | Seminal fluid | Amoxicillin-clavulanic acid | MALDI-TOF |
| Siller M et al., 2016 | 43-Male | Not described |
| Chronic prostatitis | Urethral exudate | Amoxicillin-clavulanic acid | MALDI-TOF |
| Kawahara K et al., 2018 | 29-Male | Not described |
| Prostatitis | Urine | Not described | Not described |
Presence of emerging microorganisms in the series of clinical samples.
| Microorganism | Urine Male | Urine Female | Endocervical Exudate | Urethral Exudate | Glans Exudate | Semen | Total |
|---|---|---|---|---|---|---|---|
|
| 2 | 1 | 1 | 4 | |||
|
| 2 | 2 | 1 | 1 | 2 | 1 | 9 |
|
| 1 | 1 | 2 | ||||
|
| 4 | 1 | 5 | ||||
|
| 1 | 1 | |||||
|
| 11 | 7 | 2 | 1 | 21 | ||
|
| 6 | 4 | 1 | 11 | |||
|
| 1 | 1 | |||||
|
| 1 | 1 | |||||
|
| 1 | 1 | 1 | 3 | |||
|
| 4 | 1 | 1 | 6 | |||
|
| 1 | 1 | |||||
|
| 5 | 1 | 1 | 5 | 1 | 12 | 25 |
|
| 1 | 1 | 2 | ||||
|
| 1 | 1 | |||||
|
| 2 | 2 | |||||
|
| 5 | 1 | 1 | 7 | |||
|
| 3 | 3 | |||||
|
| 1 | 1 | 1 | 1 | 1 | 2 | 7 |
|
| 9 | 29 | 10 | 1 | 10 | 59 | |
|
| 3 | 3 | |||||
|
| 3 | 3 | |||||
|
| 1 | 1 | |||||
|
| 4 | 6 | 10 | ||||
|
| 1 | 1 | |||||
|
| 4 | 4 | |||||
|
| 1 | 1 | 2 | ||||
|
| 1 | 1 | |||||
|
| 1 | 1 | 2 | ||||
|
| 2 | 2 | |||||
|
| 1 | 2 | 3 | ||||
| 19 | 72 | 3 | 91 | ||||
| 4 | 2 | 7 | 1 | 14 | |||
|
| 1 | 1 | |||||
| TOTAL | 77 | 146 | 24 | 20 | 10 | 34 | 311 |
Annualized presence of emerging microorganisms in study of genital infection in males and females.
| Microorganism | 2016 | 2017 | 2018 | 2019 | Total |
|---|---|---|---|---|---|
|
| 3 | 2 | 5 | ||
|
| 1 | 1 | |||
|
| 1 | 1 | 2 | ||
|
| 1 | 1 | |||
|
| 1 | 1 | |||
|
| 2 | 1 | 3 | ||
|
| 1 | 1 | |||
|
| 1 | 1 | |||
|
| 1 | 1 | 2 | ||
|
| 2 | 2 | |||
|
| 11 | 8 | 19 | ||
|
| 1 | 1 | |||
|
| 2 | 1 | 3 | ||
|
| 3 | 2 | 5 | ||
|
| 2 | 2 | 7 | 10 | 21 |
|
| 1 | 1 | |||
|
| 1 | 1 | |||
|
| 2 | 2 | |||
|
| 1 | 1 | 2 | ||
|
| 1 | 2 | 3 | ||
| 2 | 1 | 3 | |||
| 1 | 2 | 1 | 4 | 8 | |
|
| 1 | 1 | |||
| Total | 8 | 13 | 35 | 32 | 89 |
Percentage antibiotic susceptibility of emerging microorganisms isolated in UTI *.
| Agent | Susceptibility (%) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| P | 100 | 100 | 90 | 100 | 0 | 8 | 100 | 90 | 33 | |
| AMP | 100 | 100 | 100 | 0 | 70 | 100 | 50 | ||||
| AMC | 100 | 100 | |||||||||
| TZP | 100 | ||||||||||
|
| CTX | 100 | 100 | 100 | 100 | 14 | 100 | 100 | |||
| CFM | 0 | ||||||||||
|
| IPM | 100 | 100 | 0 | 70 | ||||||
| MEM | 100 | 90 | 100 | 29 | 100 | 100 | |||||
|
| CIP | 88 | 22 | 100 | 27 | ||||||
| LEV | 0 | 0 | 100 | 0 | 77 | 50 | |||||
| MXF | 33 | 100 | |||||||||
|
| CN | 0 | 69 | ||||||||
|
| VA | 100 | 100 | 100 | 100 | 100 | 100 | ||||
|
| TE | 100 | 100 | 92 | 21 | 100 | |||||
|
| MTZ | 0 | 0 | 0 | |||||||
|
| RD | 100 | 100 | 100 | |||||||
|
| SXT | 0 | 0 | ||||||||
| FOS | 0 | 0 | 99 | ||||||||
| F | 100 | 100 | 100 | ||||||||
* Antibiogram not performed for A. turicensis (n = 4), A. omnicolens (n = 1), or G. vaginalis (n = 38). ** Lactobacillus: crispatus, delbrueckii, fermentum, gasseri, jensenii, rhamnosus. Penicillins (Pen), Cephalosporins (Cef), Carbapenems (Carba), Quinolones (Quino), Aminoglycosides (Amg), Glycopeptides (Gcp), Tetracycline (Tetra), Nitroimidazole (Ntm), Rifampicin (Rif), Sulfamides (Sulf), Amoxicillin-Clavulanic (AMC), Ampicillin (AMP), Penicillin (P), Piperacillin-Tazobactam (TZP), Cefotaxime (CTX), Cefixime (CFM), Imipenem (IPM), Meropenem (MEM), Ciprofloxacin (CIP), Levofloxacin (LEV), Moxifloxacin (MXF), Gentamicin (CN), Teicoplanin (TEC), Vancomycin (VA), Tetracycline (TE), Metronidazole (MTZ), Rifampicin (RD), Trimethoprim-Sulfamethoxazole (SXT), Fosfomycin (FOS), Nitrofurantoin (F).
Percentage antibiotic susceptibility of emerging microorganisms isolated in urethral exudate *.
| Agents | Susceptibility (%) | |||||
|---|---|---|---|---|---|---|
|
| P | 20 | 100 | 100 | ||
| AMP | 100 | 100 | 100 | |||
| AMC | 100 | 100 | 100 | |||
|
| CTX | 40 | 100 | |||
|
| IMP | 100 | ||||
| MEM | 0 | 100 | ||||
|
| CIP | 40 | 100 | |||
| LEV | 100 | |||||
| MXF | 100 | |||||
|
| CN | 60 | ||||
|
| VA | 100 | 100 | 100 | ||
|
| TE | 100 | 60 | |||
| DO | 100 | |||||
|
| E | 0 | ||||
| AZM | 100 | |||||
|
| DA | 100 | 0 | 0 | ||
|
| LZD | 100 | ||||
|
| MTZ | 0 | 0 | |||
|
| RD | 100 | ||||
|
| SXT | 100 | 100 | 100 | ||
* Antibiogram was not performed for G. vaginalis (n = 10). Penicillins (Pen), Cephalosporins (Cef), Carbapenems (Carba), Quinolones (Quino), Aminoglycosides (Amg), Glycopeptides (Gcp), Tetracycline (Tetra), Macrolides (Mcr), Lincosamides (Linco), Oxazolidone (Oxa), Nitroimidazole (Ntm), Rifampicin (Rif), Sulfamides (Sulf), Amoxicillin-Clavulanic (AMC), Ampicillin (AMP), Penicillin (P), Piperacillin-Tazobactam (TZP), Cefotaxime (CTX), Imipenem (IPM), Meropenem (MEM), Ciprofloxacin (CIP), Levofloxacin (LEV), Moxifloxacin (MXF), Gentamicin (CN), Vancomycin (VA), Tetracycline (TE), Doxycycline (DO), Erythromycin (E), Azithromycin (AZM), Clindamycin (DA), Linezolid (LZD), Metronidazole (MTZ), Rifampicin (RD), Trimethoprim-Sulfamethoxazole (SXT).
Percentage antibiotic susceptibility of emerging microorganisms isolated in genital samples from females *.
| Agent | Susceptibility (%) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| P | 100 | 100 | 0 | 100 | 86 | |||||||
| AMP | 0 | 100 | 100 | 100 | 0 | 100 | |||||||
| AMC | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | ||||
| TZP | 100 | ||||||||||||
|
| KZ | 0 | |||||||||||
| FOX | 100 | ||||||||||||
| CXM | 100 | ||||||||||||
| CTX | 100 | 100 | 100 | 100 | 100 | 83 | |||||||
| CFM | |||||||||||||
| CAZ | 100 | ||||||||||||
| FEP | 100 | ||||||||||||
|
| ETP | 100 | |||||||||||
| IMP | 100 | 100 | 100 | 100 | 100 | ||||||||
| MEM | 100 | 100 | 100 | 100 | |||||||||
|
| ATM | 100 | |||||||||||
|
| NA | 0 | |||||||||||
| CIP | 0 | 50 | 100 | 100 | 100 | 100 | |||||||
| LEV | 100 | 100 | 100 | 100 | 50 | ||||||||
| MXF | 0 | 100 | |||||||||||
|
| AK | 100 | 100 | ||||||||||
| CN | 100 | 100 | |||||||||||
| TOB | 100 | ||||||||||||
|
| TEC | 100 | |||||||||||
| VA | 100 | 100 | 100 | 100 | 100 | ||||||||
|
| TE | 100 | 100 | 0 | |||||||||
| DO | 100 | ||||||||||||
| TGC | 100 | ||||||||||||
|
| E | 100 | 0 | 50 | |||||||||
| AZM | 33 | 0 | 100 | 0 | |||||||||
|
| DA | 0 | 0 | 100 | 50 | 100 | 83 | ||||||
|
| LZD | 100 | 100 | 100 | |||||||||
|
| MTZ | 0 | 0 | 0 | |||||||||
|
| RD | 100 | |||||||||||
|
| SXT | 100 | 0 | 100 | 100 | 100 | 100 | ||||||
* Antibiogram was not performed for A. turicensis (n = 1), A. christensenii (n = 1), or Facklamia hominis (n = 1). Penicillins (Pen), Cephalosporins (Cef), Carbapenems (Carba), Monobactams (Mbac), Quinolones (Quino), Aminoglycosides (Amg), Glycopeptides (Gcp), Tetracycline (Tetra), Macrolides (Mcr), Lincosamides (Linco), Oxazolidone (Oxa), Nitroimidazole (Ntm), Rifampicin (Rif), Sulfamides (Sulf), Amoxicillin-Clavulanic (AMC), Ampicillin (AMP), Penicillin (P), Piperacillin-Tazobactam (TZP), Cefazolin (KZ), Cefoxitin (FOX), Cefuroxime (CXM), Cefotaxime (CTX), Cefixime (CFM), Ceftazidime (CAZ), Cefepime (FEP), Ertapenem (ETP), Imipenem (IPM), Meropenem (MEM), Aztreonam (ATM), Nalidixic acid (NA), Ciprofloxacin (CIP), Levofloxacin (LEV), Moxifloxacin (MXF), Amikacin (AK), Gentamicin (CN), Tobramycin (TOB), Teicoplanin (TEC), Vancomycin (VA), Tetracycline (TE), Doxycycline (DO), Tigecillin/Tigecycline (TGC), Erythromycin (E), Azithromycin (AZM), Clindamycin (DA), Linezolid (LZD), Metronidazole (MTZ), Rifampicin (RD), Trimethoprim-Sulfamethoxazole (SXT), Daptomycin (DAP), Fosfomycin (FOS), Nitrofurantoin (F).
Percentage antibiotic susceptibility of emerging microorganisms isolated in semen and glans exudate samples *.
| Agent | Susceptibility (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
|
| P | 100 | 100 | 100 | 0 | 54 | 100 | ||
| AMP | 100 | 100 | 100 | 100 | 67 | ||||
| AMC | 100 | 100 | |||||||
|
| CTX | 100 | 100 | 100 | |||||
|
| IMP | 100 | 100 | 100 | 100 | ||||
| MEM | 100 | ||||||||
|
| CIP | 100 | 23 | 100 | |||||
| LEV | 100 | 100 | 33 | ||||||
| MXF | 100 | 0 | |||||||
|
| CN | 0 | |||||||
|
| VA | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
|
| TE | 100 | 100 | 100 | 46 | 100 | 0 | ||
|
| E | 77 | 100 | 0 | |||||
| AZM | 0 | ||||||||
|
| DA | 100 | 100 | 23 | 67 | ||||
|
| LZD | 100 | 100 | 100 | |||||
|
| MTZ | 0 | 0 | 0 | |||||
|
| RD | 100 | 100 | ||||||
|
| SXT | 0 | 100 | ||||||
| FOS | 0 | 100 | |||||||
| F | 100 | ||||||||
* Antibiogram was not performed for C. amycolatum (n = 2), G. vaginalis (n = 11), or S. viridans group (S. anginosus) (n = 1). Penicillins (Pen), Cephalosporins (Cef, Carbapenems (Carba), Quinolones (Quino), Aminoglycosides (Amg), Glycopeptides (Gcp), Tetracycline (Tetra), Macrolides (Mcr), Lincosamides (Linco), Oxazolidone (Oxa), Nitroimidazole (Ntm), Rifampicin (Rif), Sulfamides (Sulf), Amoxicillin-Clavulanic (AMC), Ampicillin (AMP), Penicillin (P), Cefotaxime (CTX), Imipenem (IPM), Meropenem (MEM), Ciprofloxacin (CIP), Levofloxacin (LEV), Moxifloxacin (MXF), Gentamicin (CN), Vancomycin (VA), Tetracycline (TE), Erythromycin (E), Azithromycin (AZM), Clindamycin (DA), Linezolid (LZD), Metronidazole (MTZ), Rifampicin (RD), Trimethoprim-Sulfamethoxazole (SXT), Daptomycin (DAP), Fosfomycin (FOS), Nitrofurantoin (F).